Michael Lutz/iStock via Getty Images Kymera entered a collaboration agreement with the French Pharma giant Sanofi (SNY) in July 2020, involving two biological targets, IRAK4, and an undisclosed target - according to Kymera's Q1 2024 quarterly report / 10Q submission: With respect to both targets, Sanofi is responsible for development, manufacturing, and commercialization of product candidates after a specified development milestone occurs with respect to each collaboration candidate. Kymera Immunology Oral ...